Tag: strategies

Riding on the bullish momentum of XRP’s recovery, PBKMiner announced the official launch of its AI-powered XRP cloud mining contracts — daily payouts, zero hardware, and full automation are now available to users worldwide.

Following ProShares’ XRP ETF filing and rising legislative clarity, investors shift to JA Mining’s daily-yield cloud mining platform

TORONTO, July 21, 2025 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) announced the pricing terms of its previously announced separate offers (the “Offers”) to purchase for cash up to the Maximum Purchase Amount (as defined in the Offer to Purchase dated July 11, 2025 (the “Offer to Purchase”), as previously amended) of its outstanding notes of the series listed in the table below (collectively, the “Notes”).

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra^® for men - in a proprietary topical formulation demonstrated to work where women need it most

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cardiac Tissue Engineering Market size & share revenue was valued at approximately USD 632.10 Million in 2024 and is expected to reach USD 735.98 Million in 2025 and is expected to reach around USD 2,943.92 Million by 2034, at a CAGR of 16.65% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott Laboratories, Artivion Inc., Athersys Inc., Baxter International Inc., Cellular Logistics Inc., Elutia Inc., Heartseed Inc., Medtronic Plc, Merck kGaA, Mesoblast Ltd., Neoolife Inc., Tejiin Limited, Terumo Corporation, and W.L. Gore & Associates, Inc and others.

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.